The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial

@article{Noseworthy1994TheIO,
  title={The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial},
  author={John H. Noseworthy and George Cornell Ebers and Margaret K. Vandervoort and Rochelle Farquhar and Elizabeth Yetisir and Robin Roberts},
  journal={Neurology},
  year={1994},
  volume={44},
  pages={16 - 16}
}
In the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: IV cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to placebo (group III: sham plasma exchange and placebo medications) using the blinded, evaluating neurologists' assessments of disease course (primary analysis). All patients were examined by both a blinded… 

Tables from this paper

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

It is suggested that mitoxantrone might be effective in reducing disease activity, both by decreasing the mean number of exacerbations and by slowing the clinical progression sustained by most patients after 1 year from the end of treatment.

Randomized controlled trials to assess therapies for multiple sclerosis

There is a crucial need to develop alternative investigative methods, possibly through enhanced collaboration across centers and with industry, and by exploring innovative techniques to use existing RCT and natural history databases to greater advantage.

Meta‐analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis

There is a need for further clinical research into the possibility of a beneficial effect of TPEX in patients with CPMS likely to experience neurologic decline over the ensuring 12 months, and targeting treatment to a particular subgroup of CPMS patients may be necessary.

An open‐trial evaluation of mitoxantrone in the treatment of progressive MS

This small, open-labeled pilot study did not provide strong support for proceeding with a randomized, controlled trial of this dosage regimen of mitoxantrone in patients with progressive MS, and comparison with two historical control groups does not suggest that mitoxanrone was efficacious.

Placebo controlled trials in neuromyelitis optica are needed and ethical.

  • B. Cree
  • Medicine
    Multiple sclerosis and related disorders
  • 2015

Blinded Outcome Assessment Was Infrequently Used and Poorly Reported in Open Trials

Blinding of outcome assessors is infrequently used and poorly reported, and increased use of independent assessors could increase the frequency of blinded assessment.

MRI findings in blinded trials should be available to treating physicians – No

It is argued that providing treating physicians access to MRI results is both unnecessary and inadvisable.

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

There is no evidence to suggest that there was widespread unblinding to treatment allocation in these three studies of Sativex and Placebo, and this methodology may be suitable for assessment of the integrity of the blind in other randomized clinical trials.
...

References

SHOWING 1-8 OF 8 REFERENCES

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Fifty-eight patients with severe, progressive multiple sclerosis were prospectively randomized to one of three treatments: 20 received intravenous ACTH, 20 received high-dose intravenous

Chronic progressive multiple sclerosis

Fifty-four patients with chronic progressive multiple sclerosis received prednisone plus oral low-dose cyclophosphamide and either true plasmapheresis (PP) or “sham” PP weekly for 20 weeks in a

Rating neurologic impairment in multiple sclerosis

A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9).

A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship

SUMMARY A generalization of the Kruskal-Wallis test, which extends Gehan's generalization of Wilcoxon's test, is proposed for testing the equality of K continuous distribution functions when

A method for assessing t h e quality of a randomized control trial

  • Controlled Clin Trials
  • 1981

Cyclophosphamide and plasma exchange in multiple selerosis [letter

  • Lancet
  • 1991